(Q38111962)

29 August 2017

title

Clinical trials of human papillomavirus vaccines and beyond (English)

1 reference

29 August 2017

1 reference

2

Joakim Dillner

1 reference

29 August 2017

Matti Lehtinen

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

4 June 2013

1 reference

Nature Reviews Clinical Oncology

29 August 2017

published in

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

400-410

1 reference

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Epidemiology of Genital Human Papillomavirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Condom use and the risk of genital human papillomavirus infection in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

The papillomavirus life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Updating the natural history of human papillomavirus and anogenital cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

HPV - immune response to infection and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Chlamydia trachomatis infection and persistence of human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Effect of smoking cessation on cervical lesion size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Human papillomavirus infections with multiple types and risk of cervical neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Human papillomavirus vaccination in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Comparing the performance of six human papillomavirus tests in a screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Addressing the vaccine confidence gap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Childhood vaccination and type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Just implementation of human papillomavirus vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Cancers attributable to human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Sound efficacy of prophylactic HPV vaccination: Basics and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

High-throughput monitoring of human papillomavirus type distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Prospects for new human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

High-risk HPV type-specific clearance rates in cervical screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Mumps and rubella eliminated from Finland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Impact of human papillomavirus vaccination depends on effective vaccination strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.84

An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in health

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23736648

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23736648

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2013.84

1 reference

29 August 2017

1 reference